(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 5.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Jazz Pharmaceuticals's revenue in 2025 is $4,086,695,000.On average, 9 Wall Street analysts forecast JAZZ's revenue for 2025 to be $255,242,077,592, with the lowest JAZZ revenue forecast at $252,352,170,614, and the highest JAZZ revenue forecast at $258,773,148,182. On average, 10 Wall Street analysts forecast JAZZ's revenue for 2026 to be $271,860,528,859, with the lowest JAZZ revenue forecast at $252,666,383,244, and the highest JAZZ revenue forecast at $290,136,542,740.
In 2027, JAZZ is forecast to generate $291,657,016,446 in revenue, with the lowest revenue forecast at $270,981,097,446 and the highest revenue forecast at $315,550,763,947.